Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of antioxidants on ocular blood flow in LPS-induced inflammation
2006-002273-41Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of PreserVision in ocular inflammation, sponsored by Medical University of Vienna. Primary endpoint: Retinal blood flow. Started May 2006; status: completed.
02
Drugs
PreserVision
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on 2006-002273-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002273-41.